Range Nuclear Renaissance ETF vs Vaxcyte Inc. Common Stock — how do they compare? Range Nuclear Renaissance ETF trades at $58.42 (market cap $668.48M), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 15.7× Range Nuclear Renaissance ETF's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Range Nuclear Renaissance ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Range Nuclear Renaissance ETF for 23 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| NUKZ | PCVX | |
|---|---|---|
Market Cap | $668.48M | $10.51B |
Volume | 55,573 | 2,644,694 |
Sector | Sector/Thematic | Health |
52-Week High | $76.23 | $73.82 |
52-Week Low | $58.42 | $40.32 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | — | $9.14B |
Signals from Pluang's Aura AI — not financial advice
NUKZ (Range Nuclear Renaissance Index ETF) trades at $60.37, showing minimal daily movement (+0.18%). The technical picture remains bearish with moving averages signaling strong selling pressure, though oscillators suggest neutral momentum. Recent industry developments include Google's 3.6 GW nuclear deal with Constellation Energy and record global nuclear power generation, creating positive sector tailwinds despite the ETF's current technical weakness.
The nuclear energy sector faces both significant catalysts and challenges. Strong demand from AI data centers and federal support for new projects provide growth opportunities, while supply chain bottlenecks and execution risks remain concerns. With the ETF trading near support levels, investors are watching for fundamental improvements to drive price recovery.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →